Glucocorticoid Induced Osteoporosis

Glucocorticoid-Induced Osteoporosis (GIOP) is a form of secondary osteoporosis caused by the chronic use of glucocorticoid medications, such as cortisone and prednisone, commonly prescribed for conditions like rheumatoid arthritis, asthma, and inflammatory disorders. Prolonged use of these medications is associated with an increased risk of bone loss and fractures. Glucocorticoids impact bone health by inhibiting bone formation, promoting bone resorption, and inducing apoptosis of osteoblasts, the cells responsible for bone formation. This imbalance leads to decreased bone mineral density and compromised bone strength. Preventive measures for GIOP include calcium and vitamin D supplementation, lifestyle modifications, and weight-bearing exercises. Bisphosphonates and other osteoporosis medications may be prescribed to mitigate bone loss in individuals at risk. Managing GIOP involves a multidisciplinary approach, with collaboration between rheumatologists, endocrinologists, and orthopaedic specialists. Regular monitoring, including bone density assessments, is crucial to identify and address bone health concerns in individuals receiving chronic glucocorticoid therapy.